An industry-first FDA approval for a nonalcoholic steatohepatitis (NASH) therapy may still be a ways off. After reviewing Intercept Pharmaceuticals’ latest application for obeticholic acid (OCA), the ...
Intercept Pharmaceuticals, long the frontrunner in non-alcoholic steatohepatitis (NASH), has suffered several delays on its FDA application for obeticholic acid (OCA). Now, the company has received an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback